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(CKD) and congestive heart failure (CHF). The objective of this study
was to investigate the impact of CM with different osmolality on
cardiac preload in patients with CKD and CHF.
METHODS 90 non-ST elevation acute coronary syndromes (NSTE-
ACS) patients with renal insufﬁciency (estimated glomerular ﬁltration
rate60 ml/min) and CHF were equally randomized to receive either
iodixanol 320 (Visipaque) or iopromide 370 (Ultravist) in PCI pro-
cesses. We applied pulse indicator continuous cardiac output (PICCO)
technology to observe the change of hemodynamic indexes in the
perioperative period. Contrast induced nephropathy (CIN) was
deﬁned as increase in serum creatinine 0.5 mg/dl or >25% from
baseline.
RESULTS Baseline characteristics were well-matched between the 2
groups. CIN developed in 21 patients (23.3%), and there was no sig-
niﬁcant difference between the iodixanol and iopromide groups (17.8%
vs. 28.9%, P¼0.213). Extravascular lung water index (EVLWI), global
end-diastolic index (GEDI) and central venous pressure (CVP) were
all signiﬁcantly increased after application of CM in the iopromide
group (13.13.8 ml/kg vs. 8.43.2 ml/kg in EVLWI; 1381472 ml/m2
vs. 962362 ml/m2 in GEDI; 145 mmHg vs. 115 mmHg in CVP; all
P<0.001), and the changes of these preload indexes in the iopromide
group were all signiﬁcantly greater than in the iodixanol group (all
P<0.05). The incidence of adverse events in terms of death, myocardial
infarction, repeat revascularization did not differ between the two
groups, but the incidence of acute heart failure in the iopromide group
was signiﬁcantly higher than the iodixanol group (P¼0.048).
CONCLUSIONS Iopromide could signiﬁcantly increase cardiac pre-
load in patients with CKD and CHF as compared to iso-osmolar CM
iodixanol, and this is associated with a higher occurrence of acute
heart failure event during the perioperative stage.
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OBJECTIVES Patients at moderate or high risk for contrast induced
nephropathy (CIN) should receive sufﬁcient hydration before contrast
application to prevent CIN. The guidelines recommend controlling
rate of ﬂuid administration in patients with heart failure, but inade-
quate hydration markedly increases the incidence of CIN. We expect
to explore an individual hydration method for patients with conges-
tive heart failure (CHF) and chronic kidney disease (CKD) to reduce
the incidence of CIN and at the same time to avoid the acute heart
failure for these patients.
METHODS This prospective, randomized, double-blind, comparative
clinical trial enrolled 264 consecutive patients with CHF and CKD
undergoing coronary procedures. These patients randomly received
either central venous pressure (CVP) guided hydration (n¼132) or
standard intravenous isotonic saline hydration (control group; n¼132).
In the CVP guided group, hydration infusion rate was automatically
adjusted according to CVP level every hour, and both study groups
received intravenous ﬂuids for the same duration but at different
rates. CIN was deﬁned as an absolute increase in serum creatinine
(SCr) > 0.5 mg/dL (44.2 mmol/L) or a relative increase >25% compared
to baseline SCr. Adverse events were assessed by 3 months follow-up
and all such events were classiﬁed by staff who were masked to
treatment assignment. This trial is registered with ClinicalTrials.gov,
number NCT02405377.
RESULTS Baseline characteristics were well-matched between the
two groups. Mean baseline SCr and the predictive CIN risk score were
comparable in the two groups. The total mean volume of isotonic
saline administered in the CVP guided hydration group is signiﬁcantly
higher than the control group (1827497 vs. 1202247; p<0.001). CIN
occurred less frequently in CVP guided hydration group than in the
control group (15.9% vs. 29.5%; p¼0.006). The incidences of acute
heart failure (acute pulmonary edema) during the perioperative
period did not differ between the two groups (6.8% vs. 7.6%;
p¼0.500). A lower incidence of cumulative 90-day adverse events
(renal replacement therapy, acute myocardial infarction, acute heart
failure and death) was also observed in CVP guided hydration patients
than in controls (8.3% vs. 20.5%; p¼0.004).
CONCLUSIONS CVP guided ﬂuid administration can safely and
effectively reduce the risk of CIN for patients with CKD and CHF.GW26-e0451
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OBJECTIVES To investigate the long noncoding RNA (lncRNA)
NONHSAT112178 as a biomarker for coronary artery disease (CAD) in
peripheral blood monocyte cells (PBMC).
METHODS RT-qPCR was performed to validate the microarray results,
ROC curve was applied to study the potential of NONHSAT112178 as a
biomarker. Diagnostic models from NONHSAT112178 alone or combi-
nation of risk factors were constructed by Fisher criteria. The function
of NONHSAT112178 was conﬁrmed in THP-1 cell line by siRNA.
RESULTS The result indicated the expression of NONHSAT112178 in
PBMCs from CAD patients increased more than twice times by
microarray analysis and RT-qPCR compared with the control group,
P<0.05. Further validated independently in a population (2020),
NONHSAT112178 expression (about 2.2-fold in CAD patients), was
consistent with the result from lncRNA microarray. The predictive
value of NONHSAT112178 was assessed in a larger population of 211
CAD patients and 171 controls. Using a diagnostic model by Fisher
criteria, considered the risk factors, the corresponding optimal
sensitivity was increased from 70.00% to 82.00%, the speciﬁcity was
slightly decreased from 94.00% to 78.00%, respectively. AUC was
increased from 0.727 to 0.785 (P¼0.001), from 0.712 to 0.768
(P¼0.010), and from 0.769 to 0.835 (P¼0.069), in original, training and
test set, respectively. Moreover, in a prospective study, we found the
sensitivity of NONHSAT112178 was increased from 68.00% to 76.00%
and speciﬁcity was decreased from 90.00% to 82.50%, respectively.
NONHSAT112178 was also found to be speciﬁc in CAD compared with
other cardiovascular diseases. Finally, we found neighboring protein-
coding gene peroxisome proliferator-activated receptor delta
(PPARD), and its target genes adipose differentiation-related protein
(ADRP) and angiopoietin-like 4 (ANGPTL4) are all transrepressed by
NONHSAT112178.
CONCLUSIONS Our present study indicated that NONHSAT112178
with function, neighboring protein-coding gene PPARD, combination
of risk factors can be used as a biomarker for CAD.
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OBJECTIVES This study was to evaluate on the prophylactic effect of
low-dose furosemide guided by left ventricular end-diastolic pressure
and brain natriuretic peptide on contrast-induced nephropathy of
patients with percutaneous coronary intervention on basis of
adequate hydration.
METHODS The patients of PCI(Percutaneous Coronary Intervention)
were recruited. The inclusion criteria: 1.male or female, 18-75 years
old; 2.sign the informed consent. Exclusion criteria: 1.inability to
obtain consent from participants; 2.primary percutaneous coronary
intervention for ST-segment elevation myocardial infarction; 3.renal
replacement therapy; 4.exposure to radiographic contrast media
within the previous 2 days; 5.allergy to radiographic contrast media;
6.acute decompensated heart failure; 7.severe valvular heart disease;
8.mechanical aortic prosthesis; 9.left ventricular thrombus; 10.history
of kidney or heart transplantation. The patients were divided into two
groups: the control group and experimental group, the basic charac-
teristics and routine examinations were recorded. All patients were
given standard hydration process according to the guideline, the
control group was administered 20 mg furosemide right after the
procedure, but the experimental group was treated individually, ac-
cording to the result of BNP(Brain Natriuretic Peptide) and LVEDP
(Left Ventricular End-Diastolic Pressure). Only the patients of
LVEDP15mmHg or BNP100pg/ml or BNP more than 50% of preop-
erative values were given 20 mg furosemide and the rest had no
special treatment. The creatinine was obtained before and 48h after
the PCI procedures, so the creatinine clearance rate and glomerular
ﬁltration rate could be calculated, also the all-cause mortality,
